A quantitative framework for the rational design of long-acting epidural therapeutics.

The development of long-acting epidural therapeutics is challenged by the confined epidural space, limited drug transport across the dura, and the rapid, drug-dependent pharmacokinetic (PK) processes in and around the spinal cord. Historically, formulation development has followed a "materials-first" trajectory, often prioritizing polymer/formulation innovation over the physiological limits of the target biological environment. Here, we present a unified quantitative framework that establishes the kinetic and loading boundaries for sustained epidural-to-cerebrospinal fluid (CSF) delivery. We demonstrate that required depot loading is governed by four critical determinants: release kinetics, epidural transfer efficiency CSF clearance, and therapeutic potency. Using dimensionless groups, our framework identifies two distinct PK design logics. For threshold-driven targets (prioritizing sustained-time coverage), first-order release imposes a "tail penalty" that exponentially increases payload requirements. This renders low-potency agents or low-efficiency delivery systems physically impractical within the constraints of the available spinal volume. Conversely, for exposure-based targets (prioritizing time-integrated concentration), the kinetic penalty is significantly reduced, approaching ideal mass-efficiency limits. To facilitate practical applications, we present problem-based design scenarios and propose a stepwise decision algorithm for feasibility screening, dose selection, and rational design of epidural depot formulations. By placing formulation design within the physiological and PK constraints of the epidural-to-CSF pathway, this Perspective provides a unifying quantitative framework for more realistic, efficient, and biologically grounded development of extended-release epidural therapeutics.